117 related articles for article (PubMed ID: 15377488)
1. 153 Samarium-EDTMP in myeloablative dosage followed by a second autotransplantation in patients with relapsed multiple myeloma.
Knop S; Dohmen BM; Kanz L; Bares R; Einsele H
Haematologica; 2004 Sep; 89(9):ECR36. PubMed ID: 15377488
[No Abstract] [Full Text] [Related]
2. A Phase II study of (153)Sm-EDTMP and high-dose melphalan as a peripheral blood stem cell conditioning regimen in patients with multiple myeloma.
Dispenzieri A; Wiseman GA; Lacy MQ; Hayman SR; Kumar SK; Buadi F; Dingli D; Laumann KM; Allred J; Geyer SM; Litzow MR; Gastineau DA; Inwards DJ; Micallef IN; Ansell SM; Porrata L; Elliott MA; Johnston PB; Hogan WJ; Gertz MA
Am J Hematol; 2010 Jun; 85(6):409-13. PubMed ID: 20513117
[TBL] [Abstract][Full Text] [Related]
3. Outcome of myeloablative allogeneic stem cell transplantation in multiple myeloma with a 153Sm-EDTMP-based preparative regimen.
Kennedy GA; Durrant S; Butler J; Morton J; Western R; Bartlett ML; Allison R; MacFarlane DJ
Leukemia; 2005 May; 19(5):879-80. PubMed ID: 15759033
[No Abstract] [Full Text] [Related]
4. Complete remission after myeloablation with bone-seeking 186Re-HEDP and high-dose melphalan followed by autologous stem cell transplantation in a patient with chemorefractory multiple myeloma.
Wiesmann A; Einsele H; Kanz L; Dohmen BM
Bone Marrow Transplant; 2005 Jul; 36(1):89-90. PubMed ID: 15895113
[No Abstract] [Full Text] [Related]
5. A phase I study of 153Sm-EDTMP with fixed high-dose melphalan as a peripheral blood stem cell conditioning regimen in patients with multiple myeloma.
Dispenzieri A; Wiseman GA; Lacy MQ; Litzow MR; Anderson PM; Gastineau DA; Tefferi A; Inwards DJ; Micallef IN; Ansell SM; Porrata L; Elliott MA; Lust JA; Greipp PR; Rajkumar SV; Fonseca R; Witzig TE; Erlichman C; Sloan JA; Gertz MA
Leukemia; 2005 Jan; 19(1):118-25. PubMed ID: 15526021
[TBL] [Abstract][Full Text] [Related]
6. Quantifying the radiation dosage to individual skeletal lesions treated with samarium-153-EDTMP.
van Rensburg AJ; Alberts AS; Louw WK
J Nucl Med; 1998 Dec; 39(12):2110-5. PubMed ID: 9867152
[TBL] [Abstract][Full Text] [Related]
7. [Inhibitory effect of samarium-153-labeled ethylenediaminetetramethylene phosphonate (EDTMP) on bone invasion and osteolysis in Walker 256 carcinoma bearing rats].
Shi B; Fu Z; Lei XH
Zhonghua Zhong Liu Za Zhi; 1997 Nov; 19(6):423-6. PubMed ID: 10920873
[TBL] [Abstract][Full Text] [Related]
8. Samarium-153-EDTMP dosimetry.
Heggie JC
J Nucl Med; 1994 Jan; 35(1):191-2. PubMed ID: 8271053
[No Abstract] [Full Text] [Related]
9. Successful treatment of POEMS syndrome with autologous hematopoietic progenitor cell transplantation.
Hogan WJ; Lacy MQ; Wiseman GA; Fealey RD; Dispenzieri A; Gertz MA
Bone Marrow Transplant; 2001 Aug; 28(3):305-9. PubMed ID: 11536000
[TBL] [Abstract][Full Text] [Related]
10. Radiopharmaceutical therapy of 5T33 murine myeloma by sequential treatment with samarium-153 ethylenediaminetetramethylene phosphonate, melphalan, and bone marrow transplantation.
Turner JH; Claringbold PG; Manning LS; O'Donoghue HL; Berger JD; Glancy RJ
J Natl Cancer Inst; 1993 Sep; 85(18):1508-13. PubMed ID: 8360933
[TBL] [Abstract][Full Text] [Related]
11. Low toxicity and efficacy of (153)samarium-EDTMP and melphalan as a conditioning regimen for secondary acute myelogenous leukemia.
Rodriguez V; Erlandson L; Arndt CA; Wiseman GA; Anderson PM
Pediatr Transplant; 2005 Feb; 9(1):122-6. PubMed ID: 15667625
[TBL] [Abstract][Full Text] [Related]
12. A phase I study of samarium-153 ethylenediaminetetramethylene phosphonate therapy for disseminated skeletal metastases.
Turner JH; Claringbold PG; Hetherington EL; Sorby P; Martindale AA
J Clin Oncol; 1989 Dec; 7(12):1926-31. PubMed ID: 2585026
[TBL] [Abstract][Full Text] [Related]
13. Skeletal uptake and soft-tissue retention of 186Re-HEDP and 153Sm-EDTMP in patients with metastatic bone disease.
Brenner W; Kampen WU; Kampen AM; Henze E
J Nucl Med; 2001 Feb; 42(2):230-6. PubMed ID: 11216521
[TBL] [Abstract][Full Text] [Related]
14. Dosimetry and toxicity of Quadramet for bone marrow ablation in multiple myeloma and other haematological malignancies.
Bartlett ML; Webb M; Durrant S; Morton AJ; Allison R; Macfarlane DJ
Eur J Nucl Med Mol Imaging; 2002 Nov; 29(11):1470-7. PubMed ID: 12397466
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of samarium-153 and holmium-166-EDTMP in the normal baboon model.
Louw WK; Dormehl IC; van Rensburg AJ; Hugo N; Alberts AS; Forsyth OE; Beverley G; Sweetlove MA; Marais J; Lötter MG; van Aswegen A
Nucl Med Biol; 1996 Nov; 23(8):935-40. PubMed ID: 9004281
[TBL] [Abstract][Full Text] [Related]
16. Marrow irradiation with high-dose 153Samarium-EDTMP followed by chemotherapy and hematopoietic stem cell infusion for acute myelogenous leukemia.
Rodriguez V; Anderson PM; Litzow MR; Erlandson L; Trotz BA; Arndt CA; Khan SP; Wiseman GA
Leuk Lymphoma; 2006 Aug; 47(8):1583-92. PubMed ID: 16966270
[TBL] [Abstract][Full Text] [Related]
17. Human pharmacokinetics of samarium-153 EDTMP in metastatic cancer.
Singh A; Holmes RA; Farhangi M; Volkert WA; Williams A; Stringham LM; Ketring AR
J Nucl Med; 1989 Nov; 30(11):1814-8. PubMed ID: 2478681
[TBL] [Abstract][Full Text] [Related]
18. Biospeciation, by potentiometry and computer simulation, of Sm-EDTMP, a bone tumor palliative agent.
Charmaine de Witt G; May PM; Webb J; Hefter G
Biometals; 1996 Oct; 9(4):351-61. PubMed ID: 8837456
[TBL] [Abstract][Full Text] [Related]
19. In focus: (166) Ho-DOTMP in the pretransplant treatment of multiple myeloma.
Clapp K
Clin Adv Hematol Oncol; 2004 Nov; 2(11):753-4. PubMed ID: 16170894
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of a freeze-dried kit for EDTMP-based bone-seeking radiopharmaceuticals.
Garnuszek P; Pawlak D; Licińska I; Kamińska A
Appl Radiat Isot; 2003 Apr; 58(4):481-8. PubMed ID: 12672628
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
